Introduction
============

Breast cancer is the second most common malignancy in Korea. The 5-year survival rate for breast cancer among Korean women has increased from 78.0% during 1993--1995 to 89.5% during 2003--2007. Despite such marked improvement, breast cancer remains the second leading cause of cancer mortality among women in Korea \[[@B1]\]. Analyzing prognostic factors associated with breast cancer survival and recurrence is important for early detection and chemotherapy.

Known prognostic indicators such as pathological criteria including tumor size, lymph-node status and hormone receptor status are pathologically used in clinical practice \[[@B2]\]. Although numerous studies have shown that disease-free survival after breast cancer treatment may be partially predicted by pathological factors \[[@B3],[@B4]\], they are not yet predicted prognostic factors for each patient in clinical practice.

Epigenetic aberrations occur in tumor cells; especially, CpG-island hypermethylation and global genomic hypomethylation are common features of breast cancer cells \[[@B5]\]. A lack of methyl supply can induce DNA global hypomethylation as well as incomplete conversion of dUMP to dTMP leading to uracil misincorporation into DNA \[[@B6]\]. One-carbon metabolism is a network of interrelated biochemical reactions that include the transfer of one-carbon groups \[[@B7]\], which have two major functions: DNA methylation and DNA synthesis \[[@B8]\].

The principal element of one-carbon metabolism is folate, since the one-carbon transfer reactions involve interconversion between several forms of this nutrient. Other important nutrients in one-carbon metabolism include vitamins B~2~, B~6~ and B~12~, which act as essential cofactors for one or more enzymes that catalyze one-carbon transfer reactions. Vitamin B~2~ is a cofactor for methylenetetrahydrofolate reductase, the critical folate-dependent enzyme. Vitamin B~6~ has a role in the conversion of tetrahydrofolate to 5, 10-methylenetetrahydrofolte, which is required for the synthesis of thymidylate and a precursor for purine synthesis \[[@B9],[@B10]\].

Previous studies have suggested that a high status of one-carbon metabolism factors has reduced the risk of several cancers, including colorectal, pancreatic, esophageal, renal cell, and breast cancer \[[@B11]-[@B15]\]. In studies related to breast cancer risk, folate has been investigated many times. Although a number of cohort and case--control studies have suggested a protective effect for a high folate status on breast cancer risk, these results are far from conclusive. And other B vitamins did not showed any associations with breast cancer risk \[[@B15]\]. For studies on one-carbon metabolism related nutrients and breast cancer survival, a few investigated the association between folate intake and breast cancer survival with inconsistent results. In a Swedish mammography study, high folate intake before breast cancer diagnosis improved the prognosis of the breast cancer and overall survival \[[@B16]\]. However, in the Long Island Breast Cancer Study Projects and Nurses' Health study, the association between vitamin B~2~, B~6~ and folate and breast cancer prognosis had null results \[[@B17],[@B18]\].

One-carbon metabolism, which requires an adequate supply of methyl group donors and B vitamins, may modify the methylation profile of the genome, thus influencing breast cancer prognosis. The aim of this study was to investigate the associations of dietary intake of vitamin B~2~, vitamin B~6~ and folate before diagnosis on the prognosis of breast cancer.

Materials and methods
=====================

Study population
----------------

A total of 1,586 newly diagnosed breast cancer cases were recruited from Seoul National University Hospital and Asan Medical Center in Korea from 2004 to 2007 \[[@B19]\]. Before any adjuvant chemotherapy and/or surgery, baseline data were collected using questionnaires. Patients with a prehistory of cancer, multiple cancers at diagnosis, distant organ metastasis at diagnosis, *in situ* breast cancer and unobtainable of dietary assessment were excluded. Subjects with a total energy intake from 500 to 3,500 kcal/day were included for the final analysis. In the final analysis, a total of 980 invasive ductal carcinoma cancer patients diagnosed with stage I - III who underwent curative resection were included.

The study was approved by the Committee on Human Research of Seoul National University Hospital (IRB No. H-0503-144-004). All participants provided informed consent before their participation in the study.

Data collection
---------------

The demographic characteristics of the participants were obtained by trained interviewers using a structured questionnaire. Information on demographic characteristics including age, education, reproductive and menstrual factors and lifestyle habits including smoking status, and alcohol consumption were collected.

A retrospective chart review was used to collect clinicopathological information including cancer stage, tumor size, lymph-node status, distant organ metastasis, estrogen receptor (ER) and progesterone receptor (PR) status, nuclear grade, surgical treatment and medical adjuvant therapy. Death was ascertained from Statistics Korea.

The food frequency questionnaire (FFQ) included 103 food items and detailed information on the FFQ has been described in a previous study \[[@B20]\]. During the in-person interviews, each participant was asked about their dietary habits for one year before the date of diagnosis. The frequency of servings was classified into nine categories: never or seldom, once a month, 2--3 times a month, one to two times a week, three to four times a week, five to six times a week, once a day, twice a day or three times or more every day. For food items with different seasonal availability, we requested that participants choose one category for how long they have eaten a particular food item from among four categories: 3, 6, 9 or 12 months. The portion size of each food item was classified as follows: small, medium or large. To help in understanding portion sizes, we provided pictures on serving sizes for food items on their corresponding pages. The reproducibility and validity of the FFQ were analyzed for 124 subjects in a previous study \[[@B20]\]. The FFQ was assessed twice at 1-year intervals for the reproducibility analysis. The correlation coefficients of the nutrients were 0.54, 0.44 and 0.43 for vitamin B~2~ (unpublished data), vitamin B~6~ and folate, respectively. FFQs were compared with 12-day diet records (3 days during each of the four seasons) for the validity analysis. The correlation coefficients of the nutrients were ranged from 0.15 to 0.31 for vitamin B~2~ (unpublished data), vitamin B~6~ and folate \[[@B20]\].

Statistical analysis
--------------------

Disease free survival (DFS) was defined as the time from the date of surgery to the date of the first locoregional recurrence, first distant metastasis, 2^nd^ primary cancer or death from any cause. Patients known to be alive with no evidence of disease were censored at the last follow-up date.

Cox's proportional hazard regression models were used to estimate the hazard ratio (HR) and 95% confidence interval (95% CI). Multivariate Model 1 included age, TNM stage, hormone status and nuclear grade while Model 2 included age, education, recruitment sites, TNM stage, hormone status and nuclear grade. In addition, one-carbon metabolism related nutrients were adjusted for total calories in both Model 1 and Model 2. The adjusted variables in Model 1 were known factors of breast cancer prognosis and the variables added to Model 2 were known factors related to the intake of nutrients. Other covariates including tumor size and lymph node status were considered but not included in the final model, since the TNM stage was adjustment variable in the final model.

We performed analyses with vitamin B~2~, vitamin B~6~ and folate as continuous variables and as categorical variables in quartiles. To further assess the combined effects of the intake of one-carbon metabolism related nutrients including vitamin B~2~, vitamin B~6~ and folate on breast cancer survival, each vitamin was coded as 0 or 1 by median, and calculated using the sum of the numbers. The combined score was categorized into three groups which were low (score, 0), medium (score, 1--2) and high (score, 3).

Wald *P* values for trends were computed by treating categorical variables as ordinal variables. *P* for interaction was analyzed by multiplying two variables.

Additionally, stratified analyses were done according to age (≤39, 40--49, 50--59, and ≥60), menopausal status, BMI group (\<25 kg/m^2^ and ≥25 kg/m^2^), alcohol consumption (\<1/month, 1+/month), TNM stage (I-II and III), lymph-node status (negative and positive), hormone status (ER + and/or PR + and ER--/PR--) and nuclear grade (I-II and III).

All statistical analyses were done using SAS statistical software version 9.2 (SAS Institute, Cary, NC).

Results
=======

The median follow-up time was 5.3 years (range, 0.2-7.0 years). There were 141 DFS events including 77 deaths from any cause among all 980 patients. Table [1](#T1){ref-type="table"} summarizes the association between demographic and clinicopathological factors and progression in breast cancer patients. In this study, breast cancer patients who were estrogen receptor negative (ER--) and progesterone receptor negative (PR--) were 39.2% and 44.2%, respectively. Among demographic factors, patients with an education higher than the college level were associated with progression of breast cancer compared to the patients with an education lower than middle school. Among clinical factors, TNM stage, tumor size, lymph node status and hormone status were significant prognostic factors for breast cancer (*P* \< 0.05).

###### 

Hazard ratios for disease progression in breast cancer patients

                             **All (N = 980)**   **Events (N = 141)**   **Model 1**^**a**^   **Model 2**^**b**^
  ------------------------- ------------------- ---------------------- -------------------- --------------------
  Age (mean(SD))                 48 (9.8)             49 (11.7)          1.02 (1.00-1.04)     1.01 (0.99-1.03)
   ≤39                          191 (19.5)            30 (21.3)                1.00                 1.00
   40-49                        422 (43.0)            50 (35.5)          0.86 (0.54-1.36)     0.76 (0.48-1.22)
   50-59                        241 (24.6)            34 (24.1)          1.02 (0.62-1.70)     0.83 (0.48-1.42)
   ≥60                          126 (12.9)            27 (19.1)          1.66 (0.97-2.82)     1.21 (0.67-2.18)
  Menopausal status                                                                                   
   Pre                          610 (63.0)            74 (53.6)                1.00                 1.00
   Post                         359 (37.0)            64 (46.4)          1.50 (0.93-2.42)     1.38 (0.85-2.25)
  BMI, kg/m^2^ (mean(SD))        23 (2.9)              23 (3.2)          0.98 (0.92-1.04)     0.97 (0.91-1.03)
   \<25                         753 (77.6)            107 (77.0)               1.00                 1.00
   ≥25                          217 (22.4)            32 (23.0)          0.85 (0.56-1.28)     0.79 (0.52-1.20)
  Education                                                                                           
   Middle school                224 (22.9)            46 (32.6)                1.00                 1.00
   High school                  402 (41.2)            56 (39.7)          0.68 (0.45-1.05)     0.69 (0.45-1.05)
   College                      351 (35.9)            39 (27.7)          0.58 (0.36-0.94)     0.58 (0.36-0.93)
  Alcohol drinking                                                                                    
   \<1/month                    559 (57.5)            85 (60.7)                1.00                 1.00
   1-3/month                    354 (36.4)            46 (32.9)          0.83 (0.57-1.21)     0.83 (0.57-1.22)
   1+/week                       59 (6.1)              9 (6.4)           1.12 (0.56-2.25)     1.09 (0.54-2.19)
  Recruited sites                                                                                     
   SNU                          511 (52.1)            73 (51.8)                1.00                 1.00
   AMC                          469 (47.9)            68 (48.2)          0.92 (0.65-1.30)     0.89 (0.63-1.26)
  TNM stage                                                                                           
   I                            400 (40.8)            25 (17.7)                1.00                 1.00
   II                           416 (42.5)            72 (51.1)          2.78 (1.74-4.44)     2.71 (1.69-4.35)
   III                          164 (16.7)            44 (31.2)          4.27 (2.57-7.11)     4.17 (2.50-6.96)
  Tumor size                                                                                          
   \<2 cm                       526 (54.9)            42 (29.8)                1.00                 1.00
   ≥2 cm                        431 (44.9)            99 (70.2)          2.57 (1.74-3.79)     2.51 (1.70-3.72)
   Tx                             2 (0.2)                                                             
  Lymph node status                                                                                   
   Negative                     577 (58.9)            60 (42.6)                1.00                 1.00
   Positive                     390 (39.8)            78 (55.3)          1.47 (1.03-2.11)     1.46 (1.02-2.09)
   Nx                            13 (1.3)              3 (2.1)                                        
  Hormone status                                                                                      
   ER + and/or PR+              698 (72.6)            74 (53.6)                1.00                 1.00
   ER--/PR--                    264 (27.4)            64 (46.4)          2.06 (1.41-3.01)     2.06 (1.40-3.02)
  Nuclear grade                                                                                       
   I-II                         525 (55.2)            57 (41.0)                1.00                 1.00
   III                          426 (44.8)            82 (59.0)          1.15 (0.78-1.69)     1.12 (0.75-1.65)

Abbreviation: AMC, Asan Medical Center; ER, estrogen receptor; PR, progesterone receptor; SNU, Seoul National University.

Data are presented as frequency (percentage), except for age and BMI in continuous variable, which are expressed as mean (SD).

^a^ Adjusted for age, TNM stage and hormone status and nuclear grade.

^b^ Adjusted for age, education, recruited site, TNM stage, hormone status and nuclear grade.

Table [2](#T2){ref-type="table"} presents the association between one-carbon metabolism related nutrients intake and disease progression in breast cancer patients. The mean intakes ± SD of vitamin B~2~, B~6~ and folate were 1.0 ± 0.4 mg, 1.5 ± 0.5 mg and 213.8 ± 99.3 mg respectively. Patients with a high (range, \> median) intake of vitamin B~2~, B~6~, and folate had an increased HR for the recurrence compared to the patients with a low (range, \< median) intake; however, the association was not statistically significant. When examining the association between the combined effects of vitamin B~2~, B~6~ and folate intake on the progression of breast cancer, the HR was 1.46 (95% CI, 0.87-2.43) for the high combined score group (range, 3) compared to the low combined score group (range, 0).

###### 

Association between one-carbon metabolism related nutrients intake and disease progression in breast cancer patients

                                **All (N = 980)**   **Events (N = 141)**   **Model 1**^**a**^   **Model 2**^**b**^
  ---------------------------- ------------------- ---------------------- -------------------- --------------------
  Vitamin B~2~ intake, mg                                                                                
   Continuous (mean(SD))            1.0 (0.4)            1.0 (0.4)          1.21 (0.67-2.18)     1.29 (0.71-2.33)
   1^st^ quartile (0.1-0.6)        192 (19.6)            29 (20.6)                1.00                 1.00
   2^nd^ quartile (0.7-0.8)        226 (23.1)            26 (18.4)          0.94 (0.54-1.61)     0.99 (0.58-1.73)
   3^rd^ quartile (0.9-1.1)        295 (30.1)            44 (31.2)          1.20 (0.71-2.02)     1.28 (0.75-2.18)
   4^th^ quartile (1.2-3.4)        267 (27.2)            42 (29.8)          1.40 (0.76-2.61)     1.58 (0.84-2.98)
   *P*~trend~                                                                     0.21                 0.12
  Vitamin B~6~ intake, mg                                                                                
   Continuous (mean(SD))            1.5 (0.5)            1.5 (0.6)          1.41 (0.90-2.20)     1.38 (0.88-2.17)
   1^st^ quartile (0.1-1.0)        174 (17.8)            26 (18.4)                1.00                 1.00
   2^nd^ quartile (1.1-1.3)        262 (26.7)            39 (27.7)          1.27 (0.75-2.16)     1.28 (0.75-2.18)
   3^rd^ quartile (1.4-1.7)        238 (24.3)            27 (19.2)          0.97 (0.72-1.80)     0.98 (0.53-1.83)
   4^th^ quartile (1.8-4.8)        306 (31.2)            49 (34.8)          1.61 (0.82-3.16)     1.65 (0.84-3.24)
   *P*~trend~                                                                     0.29                 0.27
  Folate intake, mg                                                                                      
   Continuous (mean(SD))          213.8 (99.3)          212.9 (98.3)        1.00 (0.99-1.00)     1.00 (0.99-1.00)
   1^st^ quartile (9--147)         240 (24.5)            37 (26.2)                1.00                 1.00
   2^nd^ quartile (148--199)       248 (25.3)            32 (22.7)          0.82 (0.51-1.33)     0.82 (0.51-1.34)
   3^rd^ quartile (200--256)       247 (25.2)            33 (23.4)          0.96 (0.58-1.60)     0.97 (0.58-1.63)
   4^th^ quartile (257--970)       245 (25.0)            39 (27.7)          1.18 (0.68-2.03)     1.20 (0.69-2.07)
   *P*~trend~                                                                     0.50                 0.46
  Combined score                                                                                         
   Low (0)                         302 (30.8)            44 (31.2)                1.00                 1.00
   Medium (1--2)                   289 (29.5)            35 (24.8)          0.92 (0.58-1.47)     0.93 (0.58-1.50)
   High (3)                        389 (39.7)            62 (44.0)          1.40 (0.84-2.33)     1.46 (0.87-2.43)
   *P*~trend~                                                                     0.20                 0.15

Data are presented as frequency (percentage), except for continuous variable, which are expressed as mean (SD).

^a^ Adjusted for age, TNM stage, hormone status, nuclear grade and total calorie.

^b^ Adjusted for age, education, recruited site, TNM stage, hormone status, nuclear grade and total calorie.

Table [3](#T3){ref-type="table"} presentes the association between the median of one-carbon metabolism related nutrients intake and disease progression in breast cancer patients stratified by clinicopathological characteristics. No differential association was found between the intake levels of vitamin B~2~, B~6~, and folate and disease progression stratified by TNM stage, lymph-node status, or nuclear grade. However, in ER--/PR-- breast cancers, a high intake of vitamin B~2~ and folate statistically elevated the HR of breast cancer progression compared to a low intake (HR = 2.28; 95% CI, 1.20-4.35, HR = 1.84; 95% CI, 1.02-3.32, respectively). Low *versus* high (reference = low) intake of vitamin B~6~ showed an increased HR for breast cancer progression; however, the association was not significant (P~interaction~ = 0.04, HR = 1.86; 95% CI, 0.97-3.56).

###### 

Association between median of one-carbon metabolism related nutrients and disease progression in breast cancer patients stratified by clinicopathological characteristics

                                           **Below median**   **Above median**            
  ------------------ ------------------- ------------------ ------------------ ----- ---- ------------------
                     TNM stage                                                                     
  Vitamin B~2~, mg   I-II                               350                 39   466   58  1.40 (0.85-2.30)
                     III                                 68                 16    96   28  1.13 (0.52-2.43)
  Vitamin B~6~, mg   I-II                               362                 46   454   51  1.02 (0.61-1.73)
                     III                                 74                 19    90   25  1.05 (0.49-2.27)
  Folate, mg         I-II                               397                 48   419   49  1.10 (0.69-1.75)
                     III                                 91                 21    73   23  1.52 (0.77-3.01)
                     Lymph-node status                                                             
  Vitamin B~2~, mg   Negative                           242                 25   335   35  1.28 (0.67-2.42)
                     Positive                           172                 29   218   49  1.40 (0.81-2.44)
  Vitamin B~6~, mg   Negative                           251                 28   326   32  1.22 (0.63-2.34)
                     Positive                           181                 36   209   42  0.88 (0.49-1.56)
  Folate, mg         Negative                           284                 30   293   30  1.23 (0.68-2.24)
                     Positive                           199                 38   191   40  1.12 (0.67-1.87)
                     Hormone status                                                                
  Vitamin B~2~, mg   ER + and/or PR+                    300                 34   398   40  0.91 (0.52-1.59)
                     ER--/PR--                          111                 21   153   43  2.28 (1.20-4.35)
  Vitamin B~6~, mg   ER + and/or PR+                    305                 39   393   35  0.57 (0.32-1.03)
                     ER--/PR--                          125                 26   139   38  1.86 (0.97-3.56)
  Folate, mg         ER + and/or PR+                    333                 39   365   35  0.82 (0.49-1.40)
                     ER--/PR--                          148                 30   116   34  1.84 (1.02-3.32)
                     Nuclear grade                                                                 
  Vitamin B~2~, mg   I-II                               223                 23   302   34  1.22 (0.64-2.34)
                     III                                185                 32   241   50  1.43 (0.82-2.49)
  Vitamin B~6~, mg   I-II                               226                 29   299   28  0.56 (0.28-1.11)
                     III                                200                 36   226   46  1.28 (0.73-2.24)
  Folate, mg         I-II                               250                 31   275   26  0.69 (0.38-1.27)
                     III                                224                 38   202   44  1.59 (0.95-2.66)

Abbreviation: ER, estrogen receptor; PR, progesterone receptor.

^a^ Adjusted for age, education, recruited site, TNM stage, hormone status, nuclear grade and total calorie.

Furthermore, we evaluated the association between the combined scores of one-carbon metabolism related nutrients intake and disease progression in breast cancer patients stratified by hormone status (Table [4](#T4){ref-type="table"}). The positive association between ER/PR status was profound when the nutrient intakes were categorized by combined score (P~interaction~ = 0.018). In ER--/PR-- cancers, the high combined score (range, 3) group was associated with a significantly poor DFS compared to those belonging to the low score (range, 0) group (HR = 3.84; 95% CI, 1.70-8.71).

###### 

Association between combined score of one-carbon metabolism related nutrients intake and disease progression in breast cancer patients stratified by selected characteristics

                      **Combined score**    **No. of total**   **No. of events**  **HR (95%CI)**^**a**^
  ------------------- -------------------- ------------------ ------------------- -----------------------
  Hormone status^b^                                                                
  ER + and/or PR+     Low (0)                     211                 29          1.00
                      Medium (1--2)               202                 16          0.54 (0.29-1.02)
                      High (3)                    285                 29          0.72 (0.37-1.43)
                      *P*~trend~                                                  0.29
  ER--/PR--           Low (0)                      87                 15          1.00
                      Medium (1--2)                82                 19          2.02 (0.96-4.27)
                      High (3)                     95                 30          3.84 (1.70-8.71)
                      *P*~trend~                                                  0.001

Abbreviation: ER, estrogen receptor; PR, progesterone receptor.

^a^ Adjusted for age, education, recruited site, TNM stage, hormone status, nuclear grade and total calorie.

^b^*P* for interaction = 0.018.

Discussion
==========

There was no association between one-carbon metabolism related nutrients and disease free survival of breast cancer overall, while some effects were observed when stratifying by breast cancer subtypes. To the best of our knowledge, this study is the first to systematically investigate the association between the combined effects of prediagnostic intake of nutrients related to the one-carbon metabolism pathway and the clinicopathological characteristics of breast cancer.

In our study, the range for the intake of vitamin B~2~, B~6~ and folate were 0.1-3.4 mg, 0.1-4.8 mg and 9--970 mg, respectively. These levels of vitamin B~6~ and folate were less than the tolerable upper intake level of Dietary Reference Intakes for Koreans (KDRIs). The tolerable upper intake of vitamin B~2~ level was not determinable by the KDRIs. In the KDRIs, the tolerable upper intake level of vitamin B~6~ and folate were 100 mg and 1000 mg. The levels of dietary intake of vitamin B~2~, B~6~, and folate in breast cancer patients were hardly reported. Even though there were many previous studies on the association between vitamin B~2~, B~6~ and folate and breast cancer risk, they reported the tertiles or quartile levels in both the cases and the controls. Thus, it is hard to compare the nutrients intake level of patients' with other studies that used different designs.

In observational studies, the results for the relationship between micronutrient intakes and all-cause mortality were inconsistent among breast cancer patients \[[@B21]\]. Only one study investigated one-carbon metabolism related nutrients intake and all-cause of mortality in women with breast cancer, and showed null results for vitamin B~2~, B~6~ and folate \[[@B17]\]. Few studies have investigated the association between folate intake and breast cancer survival. McEligot et al. studied 516 postmenopausal women diagnosed with breast cancer for 6.6 years (median follow-up) and showed that women in the highest tertile for dietary folate intake had an HR of 0.34 (95% CI, 0.18-0.67) regarding all-cause mortality \[[@B22]\]. In addition, in the Swedish mammography cohort, dietary folate intake was inversely associated with overall mortality (HR = 0.79; 95% CI, 0.66-0.96) \[[@B16]\]. However, in the Iowa Women's Health Study, Sellers et al. reported that among 177 breast cancer patients, folate intake had no association with breast cancer prognosis \[[@B23]\]. Moreover, in the Nurses' Health Study, Holmes et al. provided additional support for no association of breast cancer prognosis with vitamin B~2~, B~6~ and folate \[[@B18]\]. In addition, Rossi et al*.* measured the folate levels in plasma from 1024 breast cancer patients in Australia and reported that plasma folate was not significantly associated with breast cancer survival \[[@B24]\]. No other prior studies have reported the relationship between one-carbon metabolism related factors and their combined intake effects on the prognosis of breast cancer. The lack of consensus in the results of previous studies could be explained by the variation in study methodologies, micronutrient source, and total micronutrient level. Thus, it is difficult to determine how the micronutrient intake distribution reported in one study compares to other studies \[[@B25]\].

We observed that the combined intake effects of vitamin B~2~, B~6~, and folate were associated with breast cancer progression in patients depending on their ER/PR status. No previous studies examining the combined intake effects of one-carbon metabolism related nutrients intake and hormone specific breast cancer have been identified. In the Swedish Mammography Cohort (SMC), only folate intake, which is one of the one-carbon metabolism related nutrients studies, was assessed for association with breast cancer progression \[[@B20]\]. Although Harris et al. have reported that dietary folate intake has shown protective effects on breast cancer-specific mortality in ER-negative tumors, our results do not support this effect. It is difficult directly compare our study's results to theirs since the distribution of the hormone receptors in the study subjects was different (ER-negative breast cancer, less than 20% in SMC; 39.2% in the present study). For breast cancer risk, few studies have evaluated the relationship between hormone status and folate intake. A higher folate intake was associated with a lower risk of ER-negative breast cancer in the Nurses' Health Study \[[@B26]\], and in the VITamins And Lifestyle (VITAL) cohort \[[@B27]\]. In SMC, a high folate intake was related to a decreased risk of ER+/PR-- breast cancer \[[@B28]\]. Otherwise, few cohort studies have reported largely null results, with no findings for associations between folate intake and ER+, ER--, PR + or PR-- breast cancers \[[@B26],[@B27],[@B29],[@B30]\]. From various laboratory studies, their results were inconsistent with our study, which examined whether DNA methylation of the ER CpG island may play a role in suppressing ER gene expression in ER-negative breast cancer cells \[[@B31],[@B32]\]. A greater supply of methyl through a high intake of one-carbon metabolism related nutrients may induce the suppression of gene expression in patients with ER--/PR-- breast cancers. In addition, a high intake of one-carbon metabolism related nutrients may have a stronger effect on ER--/PR-- breast cancer progression than the other types of breast cancers since ER--/PR-- breast cancers are less responsive to hormone therapies. Further studies are needed to elucidate the possible association between one-carbon metabolism related nutrients and the hormone receptors in breast cancer patients.

The results of our study were contrary to the hypothesis based on previous studies that a higher intake of B vitamins would have a protective effect on breast cancer survival in population based studies. One prospective cohort study suggested the association of major energy sources with breast cancer survival may be U-shaped rather than linear \[[@B33]\]. As far as this idea, the association has not yet been proven; however, a midrange intake of vitamins is associated with the most favorable outcomes, and extremes are associated with less favorable outcomes.

This study has some limitations. First, there were likely errors in our estimate of dietary habits. Patients were asked about their dietary intake for the year preceding the diagnosis using the FFQ. Due to this, measurement errors likely occurred because of poor recall despite the validity and reproducibility evidence of the questionnaire. The FFQ correlations were lower than that reported in western countries which were between 0.5-0.7 \[[@B34]\]. In Asia, the median of the correlation coefficients for the FFQ has ranged from 0.3-0.5 in Japan \[[@B35],[@B36]\] and Korea \[[@B37],[@B38]\], and a lower FFQ correlation may have been caused by the dining etiquette and cultural foods of Korea \[[@B20]\]. Though the correlation coefficients were low, to date, FFQ is the only method in which long-term usual dietary intake of an individual can be easily obtained with a single measurement \[[@B39]\]. Second, intake of supplements was not available for the calculations. However, the intake of supplements use can improve the dietary quality for certain micronutrients \[[@B25]\]. Lastly, we could not evaluate the association between one-carbon metabolism related nutrients and breast cancer specific mortality because the data for the cause of death were not available. Thus, the results must be interpreted cautiously and need to be confirmed by a study that investigates the association of one-carbon metabolism related nutrients with breast cancer specific survival.

Nevertheless, our study has strengths. It is the first study to evaluate the association between the combined intake effects of vitamin B~2~, B~6~ and folate and hormone specific breast cancer survival.

Conclusion
==========

In summary, one-carbon metabolism related nutrients are associated with disease free survival depending on the ER/PR status among breast cancer patients. However, because of the small population in these subgroup analyses, these results should be interpreted with caution. Future studies examining the pathways of one-carbon metabolism related nutrients in certain breast cancer types must account for the direct or indirect roles of these nutrients.
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